Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The objective of this national, prospective, multi-centre observational study is to describe the prescription rational and practice in Germany, confirm the efficacy of caplacizumab in a real-world setting, and identify predicting factors in iTTP-patients with regard to persistent autoimmune activity, therapy guidance and risk of complications. The rational is to develop new treatment algorithms that optimize overall patient outcome and reduce treatment cost.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Registergroup | Patients with acquired Thrombotic Thrombocytopenic Purpura, who have been treated with caplacizumab (Cablivi®) |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Cablivi® | Drug | Intervention with Cablivi® take place outside of the study |
|
| Measure | Description | Time Frame |
|---|---|---|
| Treatment of aTTP with caplacizumab | Description of the prescription rationale and practice of caplacizumab in the treatment of aTTP | Enrollment |
| Measure | Description | Time Frame |
|---|---|---|
| Stabilization of thrombocyte | Documentation of the efficacy of caplacizumab in the treatment of aTTP outside of clinical trials (real-world data) using by means of stabilization of thrombocyte. Thrombocyte stabilization is defined as thrombocyte > 150 x 10E9/L | Enrollment |
| Normalization of LDH |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Male or female subjects with confirmed diagnosis of an acute episode of aquired thrombotic thrombocytopenic purpura, who have been treated with one dose of caplacizumab.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Linus Völker, MD | Department II of Internal Medicine, University of Cologne | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University Hospital of Cologne | Cologne | 50937 | Germany |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 41159657 | Derived | Kuhne L, Volker LA, Schonermarck U, Pfrepper C, Tzalavras A, Wendt R, Schwenger V, Schulte-Kemna L, Osterholt T, Boll B, Shimabukuro-Vornhagen A, Eisinger F, Muhlfeld A, Grasshoff L, Nitschke M, Liebregts T, Petros S, von Bergwelt-Baildon A, Kochanek M, Brinkkoetter PT, Eichenauer DA. Characteristics and Management of Patients With Immune Thrombotic Thrombocytopenic Purpura Admitted to the Intensive Care Unit: A Multicenter Retrospective Analysis. Am J Hematol. 2026 Jan;101(1):198-205. doi: 10.1002/ajh.70125. Epub 2025 Oct 29. | |
| 36696206 |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D011697 | Purpura, Thrombotic Thrombocytopenic |
| ID | Term |
|---|---|
| D011696 | Purpura, Thrombocytopenic |
| D011693 | Purpura |
| D001778 | Blood Coagulation Disorders |
| D006402 | Hematologic Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C585343 | caplacizumab |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Documentation of the efficacy of caplacizumab in the treatment of aTTP outside of clinical trials (real-world data) using by means of normalization of Lactate dehydrogenase (LDH). Normalization of LDH is defined as LDH below upper limit of normal |
| Enrollment |
| Normalization of haptoglobin | Documentation of the efficacy of caplacizumab in the treatment of aTTP outside of clinical trials (real-world data) using by means of normalization of haptoglobin. Normalization of haptoglobin is defined as haptoglobin above lower limit of normal | Enrollment |
| Risk factors for complications | Identification of risk factors for complications | Enrollment |
| Risk factors for adverse outcomes | Identification of risk factors for adverse outcomes | Enrollment |
| Risk factors for persistent autoimmune activity | Identification of risk factors for persistent autoimmune activity | Enrollment |
| Parameters for therapy guidance | Identification of parameters that guide duration and regimen of caplacizumab treatment | Enrollment |
| Effect of caplacizumab on adjunct treatments with PEX | Descriptions of the effect of caplacizumab on dose, duration and number and severity of adverse events of therapeutic plasma exchange therapy (PEX) | Enrollment |
| Effect of caplacizumab on adjunct treatments | Descriptions of the effect of caplacizumab on dose, duration and number and severity of adverse events of glucocorticoids | Enrollment |
| Derived |
| Volker LA, Kaufeld J, Balduin G, Merkel L, Kuhne L, Eichenauer DA, Osterholt T, Hagele H, Kann M, Grundmann F, Kolbrink B, Schulte K, Gackler A, Kribben A, Boss K, Potthoff SA, Rump LC, Schmidt T, Muhlfeld AS, Schulmann K, Hermann M, Gaedeke J, Sauerland K, Bramstedt J, Hinkel UP, Miesbach W, Bauer F, Westhoff TH, Bruck H, Buxhofer-Ausch V, Muller TJ, Wendt R, Harth A, Schreiber A, Seelow E, Tolle M, Gohlisch C, Bieringer M, Geuther G, Jabs WJ, Fischereder M, von Bergwelt-Baildon A, Schonermarck U, Knoebl P, Menne J, Brinkkoetter PT; German TTP-Study Group. Impact of first-line use of caplacizumab on treatment outcomes in immune thrombotic thrombocytopenic purpura. J Thromb Haemost. 2023 Mar;21(3):559-572. doi: 10.1016/j.jtha.2022.11.010. Epub 2022 Dec 22. |
| D006425 |
| Hemic and Lymphatic Diseases |
| D057049 | Thrombotic Microangiopathies |
| D013921 | Thrombocytopenia |
| D001791 | Blood Platelet Disorders |
| D000095542 | Cytopenia |
| D019851 | Thrombophilia |
| D006470 | Hemorrhage |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D012877 | Skin Manifestations |
| D012816 | Signs and Symptoms |